Other reports suggest, however, the maintenance of low doses of a TNF-α inhibitor or to continue the TNF-α inhibitor therapy during treatment of active tuberculosis; at present, the safety implications of either approach are unclear [4]-[6,13]. The gene discussed is TNF; the disease is tuberculosis.